Article in Life science alliance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Tzu-Lin ChengDepartment of Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Feixuan WuSchool of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0001-5317-0773
Md Ezazul HaqueDepartment of Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Abigail R ThielWaisman Center, University of Wisconsin-Madison, Madison, WI, USA.
Danqing WangSchool of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0001-8080-9675
Jeffrey J HelgagerDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Lingjun LiSchool of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA lp1@medicine.wisc.edu.ORCID 0000-0003-0056-3869
Luigi PuglielliDepartment of Medicine, University of Wisconsin-Madison, Madison, WI, USA lingjun.li@wisc.edu.ORCID 0000-0003-0259-8424
Funding
TR&D 2 Metabolic Labels for Ultraplexed Protein Quantification p. 453P41GM108538 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI COON, JOSHUA J · 2016 to 2025
$13.1M
Waisman Center Intellectual and Developmental Disabilities Research CenterP50HD105353 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI Qiang Chang · 2021 to 2026
$8.5M
Mass Spectrometric Studies of Neuropeptides in FeedingR01DK071801 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI · 2006 to 2026
$6.7M
Spastic paraplegia, neurodegeneration and autism: possible role for AT- 1/SLC33A1?R01NS094154 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI Luigi Puglielli · 2015 to 2026
$4.3M
Creating a region- specific biomolecular atlas of the brain of Alzheimer’s diseaseR01AG078794 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI, Luigi Puglielli · 2022 to 2026
$3.7M
Di-Leu-enabled multiplexed quantitation for biomarker discovery and validation in Alzheimer's diseaseRF1AG052324 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2018 to 2018
$2.4M
DiLeu-enabled multiplexed quantitation for biomarker discovery and validation in Alzheimer’s diseaseR01AG052324 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI · 2023 to 2026
$2.3M
Acquisition of a High-Field Dual Source FTICR-MS for Pharmaceutical ResearchS10RR029531 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2011 to 2011
$2.1M
Acquisition of a Dual-Source, High-Performance, Ion Mobility, Quadrupole Time-of-Flight Mass Spectrometry System for Biomedical Research at UW-MadisonS10OD028473 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2021 to 2021
$1.3M
ATase1 and ATase2, proteostasis, and neurological diseasesR01GM148487 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Luigi Puglielli · 2023 to 2026
$1.2M
Acquisition of a High Resolution High Speed MALDI Mass Spectrometer for Biomedical Research at UW-MadisonS10OD025084 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2018 to 2018
$598k
Mass Spectrometric Studies of Neuropeptides in FeedingR56DK071801 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2011 to 2011
Nε-lysine acetylation in the lumen of the ER requires two acetyltransferases, ATase1/NAT8B and ATase2/NAT8. They are type II membrane proteins and belong to the larger GNAT superfamily of acetyltransferases. Their enzymatic activity is tightly coupled to the import of acetyl-CoA in the lumen of the ER by AT-1/SLC33A1. Gene duplication events involving 3q25.31 (harboring
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Overexpression of ATase1 and ATase2 disrupts the secretome and causes a progeria phenotype. · full record | Socratic